

In case of emergency, or if you find this card, please contact the healthcare provider listed below.

**Erdafitinib's prescriber name:**

.....

**Prescriber's clinic, center, or hospital name:**

.....

**Prescribers' telephone number:**

.....



# Information Card for Erdafitinib-Treated Patients

## IMPORTANT MEDICAL INFORMATION INSIDE

**Erdafitinib patients:** Please carry this card, and provide it to your eye care specialist or healthcare provider at every appointment. The intent of this card is to alert your eye specialist or healthcare provider that you are receiving BALVERSA™ treatment, and of the necessary eye exams you require. For further information, please refer to the Patient Information that is provided with your treatment.

**Patient's name:** \_\_\_\_\_

I am taking the following medication: **Erdafitinib**

## **Dear Healthcare Professional,**

Eye problems are common when taking erdafitinib and can include dry or inflamed eyes, inflamed cornea (front part of the eye), and disorders of the retina including central serous retinopathy (**CSR**).<sup>1</sup>

CSR symptoms with erdafitinib treatment include blurred vision, vision loss, or any other visual changes. Patients may display no symptoms, especially if the affected areas fall outside the macula.<sup>2</sup>

**Erdafitinib-treated patients** should receive monthly eye exams during the first 4 months of treatment and every 3 months afterwards, plus at any time if experiencing vision problems.

**These examination should include:** Optical coherence tomography, visual acuity, slit lamp examination, and fundoscopy.<sup>1</sup> **If CSR is detected, please contact the prescriber of erdafitinib named on the other side of this document.**

1. Balversa™ Prescribing Information. April 2020.

2. American Society of Retina Specialists. Central serous chorioretinopathy. <https://www.asrs.org/patients/retinal-diseases/21/central-serous-chorioretinopathy>

- **Adverse events reporting guidance:**

- **Janssen scientific office:**

- Address: Building 44, North Teseen street, 5th settlement, New Cairo, P.O Box 11835, Cairo, Egypt
- Telephone: +2 21291100 Mobile: +2 01000629760
- E-mail: [JACEG-PV@its.jnj.com](mailto:JACEG-PV@its.jnj.com)

- **Egyptian Pharmaceutical Vigilance Center (EPVC) - Egyptian Drug Authority (EDA)**

- Address: 21 Abd El Aziz Al Souad Street, El Manial, Cairo, Egypt, And PO Box: 11451

- Telephone: (+2)02 25354100 ,Extension :1470
- Fax: +202 23610497 , Hotline: 15301
- E-mail: [pv.followup@edaegypt.gov.eg](mailto:pv.followup@edaegypt.gov.eg)
- Online E-reporting: <http://primaryreporting.who-umc.org/EG>

